United States Patent 5,753,646: Claim Scope, Eslicarbazepine Acetate Coverage and Patent Landscape

U.S. Patent No. 5,753,646 covers 10-substituted derivatives of 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide, including 10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide, known as eslicarbazepine acetate. The patent claims chemical compounds, specified ester species, manufacturing processes, therapeutic methods and pharmaceutical compositions.

The patent is a small-molecule composition patent, not a biologic patent. Its U.S. patent term expired in December 2015 based on the apparent U.S. filing date and standard 20-year term calculation. The patent therefore does not presently create an enforceable U.S. exclusivity barrier, although its historical claims remain relevant to prior-art, freedom-to-operate and patent-family analysis.

What drug does U.S. Patent 5,753,646 protect?

The commercially important compound associated with the patent is eslicarbazepine acetate, the active ingredient in Aptiom. The compound is a prodrug that is converted primarily to eslicarbazepine, also called licarbazepine, after administration.

The patent’s chemical platform is based on the 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide nucleus. Carbamazepine has the related dibenzazepine carboxamide structure, but the patent claims derivatives bearing a substituent at the 10-position.

Commercially relevant compound

Item	Description
Patent	U.S. Patent No. 5,753,646
Commercial active ingredient	Eslicarbazepine acetate
Chemical class	10-substituted dibenzazepine-5-carboxamides
Principal product	Aptiom
Therapeutic category	Antiseizure medicine
FDA use	Adjunctive therapy for partial-onset seizures in patients age 4 and older
Patent type	Small-molecule composition, process, method-of-use and composition claims
U.S. patent term	Expired, approximately December 2015
Biosimilar relevance	None; the product is a chemically synthesized small molecule

The supplied claims do not expressly identify the stereochemical configuration of eslicarbazepine acetate. Claim 1 covers a compound “or stereoisomer thereof.” That language is significant because it potentially reaches individual stereoisomers within the claimed chemical genus, subject to written-description, enablement and claim-construction limits.

What chemical structures are covered by claim 1?

Claim 1 is the principal genus claim. It covers a compound of general formula I, or a stereoisomer, in which the variable R may be:

Hydrogen;
Alkyl containing one to 18 carbon atoms;
Halogenalkyl;
Aralkyl;
Cycloalkyl;
Cycloalkylalkyl;
Alkoxy;
Aryl; or
Pyridyl.

The claim defines alkyl broadly as a straight or branched carbon chain containing one to 18 carbon atoms. It defines cycloalkyl as a saturated alicyclic group containing three to six carbon atoms. The permitted aryl group is unsubstituted phenyl or phenyl substituted with alkoxy, halogen or nitro.

The practical scope depends on the chemical drawing in the issued patent. Based on the listed species and process language, the intended structure is a 10-substituted ester of 10-hydroxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide. In that structure, the 10-hydroxy group is esterified with an acyl group represented by the R-containing formula.

Functional interpretation of the genus

The listed embodiments show that the patent is directed principally to compounds having the following architecture:

A dibenzazepine-5-carboxamide core.
A substituted or unsubstituted oxygen-containing group at the 10-position.
An acyl, aroyl, heteroaroyl, haloacetyl or carbonate-type substituent.
Optional stereochemistry at the 10-position.

The genus includes short-chain esters such as acetate, propionate, butyrate and pivalate; longer-chain esters such as stearate; cycloalkyl esters; aromatic esters; pyridyl esters; haloacetates; and an ethoxycarbonyl derivative.

How broad is claim 2 compared with claim 1?

Claim 2 is narrower than claim 1 because it identifies 31 specific compounds. It includes the acetate, benzoylate, methoxybenzoylate, nitrobenzoylate, chlorobenzoylate, aliphatic carboxylates, cycloalkyl carboxylates, phenylacetates, pyridine carboxylates, haloacetates, formate and ethoxycarbonyl derivatives.

The first listed species is:

10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide

That is the compound generally associated with eslicarbazepine acetate.

Claim 2 species map

Category	Examples in claim 2	Commercial significance
Simple aliphatic esters	Acetate, propionate, butyrate, pivalate	Establishes a prodrug series
Long-chain ester	Stearate	May affect lipophilicity and release
Cycloalkyl esters	Cyclopentanoyloxy, cyclohexanoyloxy	Broadens non-aromatic ester coverage
Aromatic esters	Benzoyloxy and substituted benzoyloxy compounds	Covers phenyl-based acyl groups
Methoxybenzoyl derivatives	Ortho-, meta- and para-methoxy	Positional-isomer coverage
Nitrobenzoyl derivatives	Ortho-, meta- and para-nitro	Positional-isomer coverage
Haloacetates	Chloroacetoxy and bromoacetoxy	Reactive or polarity-modifying esters
Pyridyl esters	Nicotinoyloxy and isonicotinoyloxy	Heteroaromatic coverage
Carbonate-type derivative	Ethoxycarbonyloxy	Extends beyond simple carboxylate esters

Claim 2 is useful in infringement analysis because an accused product does not need to fall within every possible embodiment of claim 1 if it matches one of the expressly listed species. Conversely, a product outside the 31 listed compounds may still infringe claim 1 if it satisfies the broader structural limitations.

What does the process claim cover?

Claim 3 covers a process for producing a compound within the claim 1 genus by reacting the underlying 10-hydroxy dibenzazepine carboxamide intermediate with a reagent of general formula III:

A-CO-R

The variable A may be hydrogen, halogen, an oxygen-carbonyl group or an oxygen-carbonyl-alkoxy group. Claim 4 narrows the process by requiring at least one condensing agent or base.

The process claims appear directed to esterification or related acylation chemistry. They may cover reactions using acid halides, anhydrides, carboxylic acids or carbonate-forming reagents, depending on the precise formula and specification disclosure.

Process-claim limitations

A process infringement analysis would require proof of:

Use of the claimed dibenzazepine starting material;
Reaction with a reagent falling within the specified A-CO-R formula;
Formation of a compound within claim 1;
For claim 4, use of a condensing agent or base.

A manufacturer could avoid a process claim by using a different starting material, a different protecting-group strategy, a different activation method or a route that does not satisfy the claimed reagent limitations. The composition claims are therefore more commercially important than the process claims for finished-product enforcement.

What therapeutic methods are covered?

Claims 5 and 7 are method-of-treatment claims. They cover administering an effective amount of a pharmaceutical composition containing a compound within claim 1 or claim 2 to a subject afflicted with:

Epilepsy;
Trigeminal neuralgia;
Affective brain disorder; or
Nervous-function alteration in degenerative and post-ischemic disease.

Claim 6 requires a pharmaceutically acceptable carrier. Claim 8 is intended to impose a corresponding carrier limitation on claim 7, but the supplied text refers to “a compound of claim 1” rather than “a compound of claim 2.” That apparent dependency error could affect claim construction and validity, depending on the issued text, prosecution history and applicable correction doctrines.

Method-of-use exposure

The method claims are broad in disease-category terms but lack detailed dosing limitations. They do not appear limited to:

A specific dose;
A particular dosage interval;
A particular patient age;
A particular formulation;
A specific route of administration;
A defined level of seizure control; or
A particular eslicarbazepine metabolite concentration.

A generic applicant could face method-of-use issues if its labeling actively directs use for a patented indication. In practice, those risks depend on the patent’s enforceable term, the approved label, any skinny-label strategy and whether the claimed indication remains protected by an unexpired continuation or later patent.

What pharmaceutical compositions are protected?

Claims 9 and 10 cover pharmaceutical compositions containing a claim 1 or claim 2 compound in admixture with a pharmaceutically acceptable carrier.

These are formulation-adjacent claims, but they are not detailed formulation claims. The claims do not specify:

Tablet composition;
Capsule composition;
Immediate-release or extended-release performance;
Particle size;
Salt form;
Excipient identity;
Dissolution profile;
Bioavailability threshold;
Solid-state form; or
Manufacturing parameters.

The scope is therefore principally composition-based. A tablet, capsule or other dosage form containing a covered active compound could fall within the claims if the compound and carrier limitations are met.

Are formulation patents separate from Patent 5,753,646?

The patent does not appear to claim a sophisticated formulation platform. It claims a pharmaceutical composition in broad carrier language. Later patents associated with a commercial product may protect dosage forms, solid forms, manufacturing controls, dosing regimens or other product-specific attributes. Those later rights must be assessed separately from U.S. Patent 5,753,646.

The expiration of this patent does not establish freedom to operate against every later patent covering eslicarbazepine acetate or an Aptiom formulation.

When did U.S. Patent 5,753,646 lose exclusivity?

The patent’s ordinary U.S. term appears to have ended in December 2015, calculated from the U.S. filing date under the 20-year term applicable to post-1995 applications. The patent issued on May 19, 1998. Patent term adjustment, terminal disclaimers and patent-term extension should be checked against the official USPTO record before relying on a day-specific expiration calculation. [1]

Exclusivity timeline

Event	Approximate date
Earliest priority	December 1994
U.S. filing	December 1995
Patent issued	May 19, 1998
Standard 20-year U.S. term endpoint	December 2015
FDA approval of Aptiom	2013
Current status of Patent 5,753,646	Expired

FDA regulatory exclusivity is distinct from patent term. A period of FDA new-drug exclusivity may have restricted certain generic approvals, but it does not revive an expired patent. FDA product exclusivity and Orange Book patent listings must be reviewed separately. [2, 3]

What is the Orange Book status of U.S. Patent 5,753,646?

U.S. Patent 5,753,646 has been associated with the Aptiom regulatory product and its active ingredient, eslicarbazepine acetate. The Orange Book identifies patents submitted by an NDA holder, but listing does not establish validity or infringement. An Orange Book listing also does not confirm that every claim covers the approved product.

For an expired patent, the practical Orange Book consequence is limited. A generic applicant may still have needed to address the patent during the period when it was listed and unexpired, but an expired patent does not support a prospective injunction against a new generic launch.

Regulatory distinction

Issue	Effect
Orange Book listing	Identifies an NDA sponsor-submitted patent
Patent expiration	Ends enforceable patent exclusivity
FDA exclusivity	Operates independently from patent term
Paragraph IV certification	Relevant principally while a listed patent remains unexpired
Generic approval	Depends on ANDA requirements, exclusivity, labeling and remaining patents

Were there Paragraph IV challenges or patent settlements?

The supplied claims establish no Paragraph IV certification, ANDA filing, patent lawsuit or settlement agreement. The patent number alone cannot establish which companies challenged the patent or whether a settlement restricted generic launch.

The commercially relevant risk assessment is historical rather than prospective because the patent’s ordinary term ended in 2015. Any current generic-entry analysis must focus on later unexpired patents, regulatory exclusivity, formulation rights, manufacturing rights and contractual restrictions.

Which companies are associated with the product and patent estate?

Bial developed eslicarbazepine acetate, while Sunovion Pharmaceuticals commercialized Aptiom in the United States. The relevant commercial landscape has included:

Bial as the originator and development company;
Sunovion as the U.S. commercial sponsor for Aptiom;
Generic manufacturers pursuing abbreviated approval for eslicarbazepine acetate;
Potential later patent holders covering formulations, dosing, solid forms or manufacturing processes.

The identity of the current patent owner should be verified in the USPTO assignment database. Assignment records can separate legal ownership from licensing, marketing and regulatory sponsorship. [4]

How strong is the patent estate for eslicarbazepine acetate?

U.S. Patent 5,753,646 was potentially strong during its enforceable term because claim 1 was a composition claim covering a genus of compounds, while claim 2 expressly listed the acetate species. Composition claims generally provide a more direct infringement theory than process claims or method claims.

Its current strength is limited by expiration.

Historical strengths

Express coverage of the acetate species;
Broad genus covering multiple acyl substituents;
Stereoisomer language;
Separate process claims;
Separate treatment-method claims;
Pharmaceutical composition claims.

Potential validity pressure points

Prior art involving carbamazepine or 10-hydroxy carbamazepine derivatives;
Obviousness of esterifying a known hydroxy compound;
Written-description support for the full R-variable genus;
Enablement across C1-C18 alkyl, aryl, heteroaryl and cycloalkyl embodiments;
Claim clarity caused by formula and dependency errors;
Double-patenting issues against related applications;
Adequacy of support for broad therapeutic indications.

The strongest historical enforcement position would likely have centered on a commercial product containing the expressly claimed 10-acetoxy compound. A generic product containing the same active ingredient would have been exposed to the composition claims during the patent term, subject to validity and noninfringement defenses.

What generic launch scenarios existed?

During the patent term, generic manufacturers had several possible routes:

Paragraph IV challenge. Argue that the patent was invalid, unenforceable or not infringed.
Paragraph III certification. Accept the patent and defer approval until expiration.
Skinny-label strategy. Remove patented indications from the proposed label, subject to inducement and labeling analysis.
Design-around chemistry. Develop a different active compound, although this would not be an equivalent generic of eslicarbazepine acetate.
Post-expiration launch. Enter after the patent term and address only remaining regulatory and patent barriers.

Because claim 2 expressly recites the acetate compound, chemical design-around options would not preserve an equivalent eslicarbazepine acetate product while avoiding that claim.

What geographic coverage did the patent provide?

U.S. Patent 5,753,646 provided rights only in the United States. Foreign counterparts, European patents and national patents in other jurisdictions required separate validity, ownership and expiration analysis.

The expiration of the U.S. patent had no automatic legal effect in Europe, Canada, Japan or other markets. Conversely, foreign patent expiration did not authorize U.S. manufacture, use, sale or importation during the U.S. term.

What manufacturing and intellectual-property barriers remain?

The expired patent no longer blocks manufacture or sale in the United States. Remaining barriers may include:

Later composition or formulation patents;
Solid-state or polymorph patents;
Manufacturing-process patents;
Dosing-regimen patents;
Patent rights covering combination therapy;
Regulatory exclusivity;
Trade secrets involving process scale-up and impurity control;
Licensing restrictions or territorial commercialization agreements.

The process claims in Patent 5,753,646 could historically have created manufacturing risk, but they were narrower than the composition claims. A noninfringing process could avoid claims 3 and 4 while still producing a compound that would have infringed claims 1, 2, 9 or 10 during the patent term.

Key Takeaways

U.S. Patent 5,753,646 covers a genus of 10-substituted dibenzazepine-5-carboxamides.
Claim 2 expressly lists 10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide, the compound associated with eslicarbazepine acetate.
Claims 3 and 4 cover selected esterification and acylation processes.
Claims 5 through 8 cover treatment of epilepsy and specified neurological disorders.
Claims 9 and 10 cover pharmaceutical compositions containing the claimed compounds.
The patent is a small-molecule patent and has no biosimilar pathway relevance.
Its ordinary U.S. patent term ended in approximately December 2015.
Current generic-entry risk must be assessed against later patents and regulatory exclusivities, not this expired patent alone.
The patent’s historical composition claims were more significant than its process claims for infringement exposure.
Claim 8 contains an apparent dependency error that could have affected construction and validity.

FAQs

Does U.S. Patent 5,753,646 cover eslicarbazepine itself?

The patent expressly covers eslicarbazepine acetate and related 10-substituted derivatives. Eslicarbazepine, the hydroxy metabolite, is structurally distinct from the acetate ester and should not automatically be treated as within every claim.

Is Aptiom still protected by this patent?

No. U.S. Patent 5,753,646 no longer provides enforceable U.S. exclusivity because its patent term expired in approximately December 2015.

Is eslicarbazepine acetate a biologic requiring a biosimilar application?

No. Eslicarbazepine acetate is a chemically synthesized small molecule. Generic versions generally proceed through the ANDA pathway rather than the biosimilar pathway.

Can a company manufacture eslicarbazepine acetate outside the United States?

The U.S. patent did not control activity wholly outside the United States. Foreign patents, export rules, destination-country rights and later patent families may still apply.

Did claim 8’s reference to claim 1 invalidate the entire patent?

Not automatically. The effect would depend on the issued claim language, prosecution history, claim-construction principles and whether the error could be corrected or interpreted consistently with the specification. An apparent dependency defect generally requires claim-specific analysis.

References

United States Patent and Trademark Office. (1998). U.S. Patent No. 5,753,646.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2013). Aptiom (eslicarbazepine acetate) prescribing information.
United States Patent and Trademark Office. (n.d.). Patent assignment search.
35 U.S.C. § 154. (2024). Patent term and adjustment provisions.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Portugal	101732	Jun 30, 1995

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0751129	⤷ Start Trial	SPC027/2009	Ireland	⤷ Start Trial
European Patent Office	0751129	⤷ Start Trial	CA 2009 00023	Denmark	⤷ Start Trial
European Patent Office	0751129	⤷ Start Trial	C300406	Netherlands	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,753,646

Summary for Patent: 5,753,646